Spots Global Cancer Trial Database for regorafenib
Every month we try and update this database with for regorafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | NCT03992456 | Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re... | Panitumumab Quality-of-Life... Questionnaire A... Regorafenib Trifluridine an... | 18 Years - | Academic and Community Cancer Research United | |
| Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer | NCT02619435 | Advanced Colore... | regorafenib | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | NCT05535647 | Intrahepatic Ch... | Regorafenib and... FOLFOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Study of Ruxolitinib in Colorectal Cancer Patients | NCT02119676 | CRC (Colorectal... | Ruxolitinib Regorafenib Placebo | 18 Years - | Incyte Corporation | |
| Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer | NCT04110093 | Colorectal Canc... Immunotherapy | Regorafenib and... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT02278783 | Ovarian Cancer Primary Periton... Fallopian Tube ... | regorafenib | 18 Years - | University of Utah | |
| Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | NCT02795156 | Non-small Cell ... Urothelial Carc... Gastrointestina... Upper Aerodiges... | Afatinib Regorafenib Cabozantinib | 18 Years - | SCRI Development Innovations, LLC | |
| Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy | NCT03305913 | Pretreated Meta... | TAS 102 Regorafenib | 18 Years - | AIO-Studien-gGmbH | |
| REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression | NCT02584465 | Ovarian Carcino... | Tamoxifen Regorafenib | 18 Years - | ARCAGY/ GINECO GROUP | |
| [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib | NCT02175095 | Colorectal Canc... | Regorafenib | 20 Years - | Asan Medical Center | |
| Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer | NCT05425940 | Colorectal Canc... | XL092 Atezolizumab Regorafenib | 18 Years - | Exelixis | |
| Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients | NCT05426811 | Regorafenib Raltitrexed Colorectal Neop... Third-line Trea... | Regorafenib Raltitrexed | 18 Years - | China Medical University, China | |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | NCT04362839 | Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... | Ipilimumab Nivolumab Regorafenib | 18 Years - | City of Hope Medical Center | |
| Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | NCT04008511 | Metastatic Colo... | Regorafenib Regorafenib Capecitabine Oxaliplatin | 18 Years - 75 Years | China Medical University, China | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | NCT05717738 | Hepatocellular ... | TACE Lenvatinib Anti-PD-1 monoc... Bevacizumab Bio... Bevacizumab plu... apatinib plus c... Sorafenib Donafenib Regorafenib | 18 Years - | Tongji Hospital | |
| Regorafenib in Relapsed Glioblastoma | NCT02926222 | Glioblastoma Mu... | Regorafenib Lomustine | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients | NCT01189903 | Asian Colorecta... | Regorafenib | 21 Years - | National University Hospital, Singapore | |
| Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC | NCT04718909 | Hepatocellular ... | Regorafenib + s... Regorafenib | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) | NCT01929616 | Advanced Chemor... | regorafenib | 18 Years - | Jules Bordet Institute | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Regorafenib in Metastatic Colorectal Cancer | NCT02466009 | Metastatic Colo... | Regorafenib | 70 Years - | University of Rochester | |
| Phase II Study of Regorafenib as Maintenance Therapy | NCT03793361 | Metastatic Soft... | Regorafenib Placebo | 18 Years - | Centre Oscar Lambret | |
| Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | NCT04327700 | Hepatocellular ... | TheraBionic Regorafenib | 18 Years - | Wake Forest University Health Sciences | |
| Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer | NCT05462613 | Metastatic Colo... | quality of life... Blood sample Regorafenib Metronomic chem... Aspirin Bevacizumab FOLFIRI or FOLF... | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs | NCT02889328 | Gastrointestina... | Regorafenib | 20 Years - | Asan Medical Center | |
| Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | NCT02934529 | Metastatic Colo... | Irinotecan Folinic Acid 5-FU 5-FU Cetuximab Bevacizumab Capecitabine regorafenib Irinotecan 125m... Cetuximab wkly | 18 Years - | Ludwig-Maximilians - University of Munich | |
| (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | NCT03465722 | GIST | avapritinib regorafenib | 18 Years - | Blueprint Medicines Corporation | |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | NCT02955940 | Pancreatic Canc... Colorectal Canc... Breast Cancer Lung Cancer | Ruxolitinib Capecitabine Regorafenib | 18 Years - | Incyte Corporation | |
| Regorafenib Post-marketing Surveillance in Japan | NCT01933958 | Gastrointestina... | Regorafenib (St... | - | Bayer | |
| A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours | NCT05644392 | Advanced Biliar... | Cadonilimab Inj... Regorafenib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | NCT02587650 | ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib | 18 Years - | University of California, San Francisco | |
| Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) | NCT04170556 | Hepatocellular ... | Regorafenib Nivolumab | 18 Years - | Fundacion Clinic per a la Recerca Biomédica | |
| Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma | NCT01774344 | Carcinoma, Hepa... | Regorafenib (St... Placebo | 18 Years - | Bayer | |
| Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer | NCT02116894 | Colorectal Canc... | PF-03446962 Regorafenib | 18 Years - | Duke University | |
| Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma | NCT02098538 | Adenoid Cystic ... | Regorafenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | NCT03555149 | Colorectal Canc... | Regorafenib Atezolizumab Imprime PGG Bevacizumab Isatuximab Selicrelumab Idasanutlin AB928 LOAd703 | 18 Years - | Hoffmann-La Roche | |
| Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | NCT05962450 | Hepatocellular ... | iNKT Cells PD-1 Regorafenib | 18 Years - 75 Years | Beijing YouAn Hospital | |
| Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation | NCT02606097 | Gastrointestina... | regorafenib | 20 Years - | Chang Gung Memorial Hospital | |
| Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | NCT02316340 | Colorectal Canc... | Vorinostat Hydroxychloroqu... Regorafenib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Effect of Neomycin on the Pharmacokinetics of Regorafenib | NCT02001909 | Neoplasms | Regorafenib (St... Neomycin | 18 Years - 45 Years | Bayer | |
| Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer | NCT03627728 | Gastric Cancer | Regorafenib placebo | 18 Years - | Gruppo Oncologico Italiano di Ricerca Clinica | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | NCT02587650 | ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib | 18 Years - | University of California, San Francisco | |
| Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients | NCT03829852 | Metastatic Colo... | Regorafenib | 20 Years - | Taipei Veterans General Hospital, Taiwan | |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | NCT03970447 | Glioblastoma | Temozolomide Lomustine Regorafenib Radiation Paxalisib VAL-083 VT1021 Troriluzole ADI-PEG 20 | 18 Years - | Global Coalition for Adaptive Research | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Optimization for Regorafenib in HCC | NCT04476329 | Hepatocellular ... | Regorafenib 40 ... | 18 Years - | SC Liver Research Consortium, LLC | |
| Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma | NCT05622136 | Liver Cancer Hepatocellular ... | Regorafenib Ora... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer | NCT05425940 | Colorectal Canc... | XL092 Atezolizumab Regorafenib | 18 Years - | Exelixis | |
| Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | NCT02368886 | Colon Adenocarc... Rectal Adenocar... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... | Clobetasol Prop... Pharmacological... Quality-of-Life... Regorafenib | 18 Years - | Academic and Community Cancer Research United | |
| Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients | NCT04698785 | Bone Sarcoma Osteosarcoma | Treatment by re... Treatment by pl... | 12 Years - | Centre Leon Berard | |
| Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting | NCT02310477 | Metastatic Colo... | regorafenib | 18 Years - | Centre Oscar Lambret | |
| Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | NCT02934529 | Metastatic Colo... | Irinotecan Folinic Acid 5-FU 5-FU Cetuximab Bevacizumab Capecitabine regorafenib Irinotecan 125m... Cetuximab wkly | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors. | NCT02106845 | Neoplasms | Digoxin Rosuvastatin Regorafenib (St... | 18 Years - | Bayer | |
| Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer | NCT05425940 | Colorectal Canc... | XL092 Atezolizumab Regorafenib | 18 Years - | Exelixis | |
| Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | NCT05962450 | Hepatocellular ... | iNKT Cells PD-1 Regorafenib | 18 Years - 75 Years | Beijing YouAn Hospital | |
| KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer | NCT05985109 | Colorectal Canc... | KN046 regorafenib | 18 Years - | Peking University Cancer Hospital & Institute | |
| Regorafenib and Cetuximab in Patients With Advanced Malignancy | NCT02095054 | Advanced Cancer... | Regorafenib Cetuximab Questionnaire | 12 Years - | M.D. Anderson Cancer Center | |
| Regorafenib and Nivolumab Simultaneous Combination Therapy | NCT03406871 | Advanced and Me... | Regorafenib Nivolumab | 20 Years - | National Cancer Center Hospital East | |
| A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | NCT04200404 | Advanced Refrac... | CS1001 Regorafenib | 18 Years - | CStone Pharmaceuticals | |
| Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer | NCT05023720 | Metastatic Colo... | nonintervention | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) | NCT02788279 | Colorectal Canc... | Atezolizumab (M... Cobimetinib Regorafenib | 18 Years - | Hoffmann-La Roche | |
| Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | NCT03081494 | Metastatic Colo... | spartalizumab (... regorafenib | 18 Years - | Novartis | |
| Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors | NCT01096030 | Neoplasms | Regorafenib (St... | 18 Years - | Bayer | |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | NCT01466504 | Renal Cell Carc... Hepatocellular ... Colorectal Carc... | skin punch biop... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer | NCT03828799 | Metastatic Colo... | Folfirinox + re... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | NCT04055220 | Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma | Treatment by Re... Treatment by Pl... | 12 Years - | Centre Leon Berard | |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | NCT01466504 | Renal Cell Carc... Hepatocellular ... Colorectal Carc... | skin punch biop... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Biomolecular Analysis for Predicting Response to Regorafenib | NCT05759195 | Glioblastoma Glioblastoma, I... | Biomolecular tu... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Efficacy of Ginseng for Patients on Regorafenib | NCT02581059 | Colorectal Canc... Palliative Medi... Supportive Care | Regorafenib Ginseng | 18 Years - | Hoosier Cancer Research Network | |
| Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | NCT02316340 | Colorectal Canc... | Vorinostat Hydroxychloroqu... Regorafenib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC | NCT02835924 | Metastatic Colo... | Regorafenib | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer | NCT02910843 | Rectal Cancer | Regorafenib Capecitabine Radiotherapy Surgery | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients | NCT06095375 | Glioblastoma, I... MGMT-Methylated... | Regorafenib Temozolomide | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST | NCT02164240 | Gastrointestina... | Sunitinib Regorafenib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Regorafenib in Patients With Advanced Myeloid Malignancies | NCT03042689 | Acute Myeloid L... | Regorafenib | 18 Years - | Massachusetts General Hospital | |
| Zinc Supplement in Regorafenib Treated mCRC Patient | NCT03898102 | Colorectal Canc... | Regorafenib Zinc gluconate ... | 20 Years - | Chang Gung Memorial Hospital | |
| An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | NCT03377361 | Colorectal Canc... Colorectal Tumo... Colorectal Carc... Colorectal Neop... | Nivolumab Trametinib Ipilimumab Regorafenib | 18 Years - | Bristol-Myers Squibb | |
| Regorafenib in Relapsed Glioblastoma | NCT02926222 | Glioblastoma Mu... | Regorafenib Lomustine | 18 Years - | Istituto Oncologico Veneto IRCCS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
